Log Out

Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4%

Defense World · Jan 1, 2023 04:21

Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) fell 4% during mid-day trading on Friday . The stock traded as low as $14.48 and last traded at $14.50. 4,560 shares changed hands during trading, a decline of 98% from the average session volume of 182,819 shares. The stock had previously closed at $15.11.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price objective on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, November 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Repare Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $31.50.

Get Repare Therapeutics alerts:

Repare Therapeutics Trading Down 2.6 %

The business's 50-day moving average is $15.53 and its two-hundred day moving average is $13.91. The stock has a market capitalization of $617.23 million, a PE ratio of -20.15 and a beta of 0.06.

Insider Buying and Selling

In related news, Director Davis Jerel sold 250,000 shares of the company's stock in a transaction on Friday, December 9th. The shares were sold at an average price of $16.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the director now directly owns 2,094,451 shares of the company's stock, valued at approximately $33,511,216. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 33.60% of the stock is owned by corporate insiders.

Institutional Trading of Repare Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Bartlett & Co. LLC purchased a new position in Repare Therapeutics in the 2nd quarter valued at about $28,000. UBS Group AG boosted its position in Repare Therapeutics by 26.3% in the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock valued at $43,000 after buying an additional 739 shares during the last quarter. Bpifrance SA purchased a new position in Repare Therapeutics in the 2nd quarter valued at about $113,000. Tower Research Capital LLC TRC purchased a new position in Repare Therapeutics in the 3rd quarter valued at about $113,000. Finally, Fox Run Management L.L.C. purchased a new position in Repare Therapeutics in the 3rd quarter valued at about $143,000. 78.19% of the stock is owned by hedge funds and other institutional investors.

About Repare Therapeutics

(Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.